Got this from my newsbot....
Press Release Source: Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals' SRT501 Slows Retinal Ganglion Cell Loss During Optic Neuritis in a Preclinical Model of Multiple Sclerosis
Tuesday March 4, 8:00 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT - News), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that Kenneth Shindler, MD, PhD, University of Pennsylvania Scheie Eye Institute in Philadelphia, will present preclinical data at the North American Neuro-Ophthalmology Society annual meeting showing that SRT501, when orally administered, slows retinal ganglion cell loss during optic neuritis, a neurodegenerative eye disorder, and suppresses neurological dysfunction in a preclinical model of Multiple Sclerosis. Sirtris Pharmaceuticals Senior Vice President of Development Peter Elliott, PhD, is a co-author of this research.
The presentation will be held on Monday, March 10, 2008 in Orlando, FL.